Changchun University of Chinese Medicine, 1035 Boshuo Road, Changchun, Jilin, China.
Affiliated Hospital of Changchun University of Chinese Medicine, 1478 Gongnong Road, Changchun, Jilin, China.
Medicine (Baltimore). 2021 Dec 17;100(50):e28277. doi: 10.1097/MD.0000000000028277.
Knee osteoarthritis (KOA) is a chronic degenerative disease involving cartilage and surrounding tissues. It causes a huge burden to social and medical resources and seriously affects people's living and working ability. In recent years, people have become increasingly interested in the application of Chinese medicine monomers to treat KOA. Among them, icariin plays an important role in the clinical treatment of KOA. Therefore, to evaluate the effectiveness and safety of icariin in the treatment of KOA, we conducted this study to provide a new basis for the clinical treatment of KOA.
We propose a systematic search of the PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and China Biomedical databases for all randomized controlled trials examining the use of icariin in the treatment of KOA patients up to October 20, 2021. The screening and data extraction processes will be performed independently by 2 researchers. We will use the Cochrane risk bias assessment tool to evaluate the quality of the studies that met the inclusion criteria. The data will be statistically analyzed using RevMan5.3 software.
This study will provide high-quality evidence for the effectiveness and safety of icariin in the treatment of KOA.
The purpose of this study was to explore the efficacy of icariin in the treatment of KOA and to provide clinicians and patients with new treatment strategies.
INPLASY2021110015.
膝骨关节炎（KOA）是一种涉及软骨和周围组织的慢性退行性疾病。它给社会和医疗资源带来了巨大的负担，严重影响了人们的生活和工作能力。近年来，人们对中药单体治疗 KOA 的应用越来越感兴趣。其中，淫羊藿苷在 KOA 的临床治疗中起着重要作用。因此，为了评估淫羊藿苷治疗 KOA 的有效性和安全性，我们进行了这项研究，为 KOA 的临床治疗提供新的依据。
我们建议对 PubMed、Embase、Web of Science、Cochrane 图书馆、中国国家知识基础设施、万方和中国生物医学数据库进行系统搜索，以查找截至 2021 年 10 月 20 日所有使用淫羊藿苷治疗 KOA 患者的随机对照试验。筛选和数据提取过程将由 2 名研究人员独立进行。我们将使用 Cochrane 风险偏倚评估工具来评估符合纳入标准的研究的质量。使用 RevMan5.3 软件对数据进行统计分析。
这项研究将为淫羊藿苷治疗 KOA 的有效性和安全性提供高质量的证据。
本研究旨在探讨淫羊藿苷治疗 KOA 的疗效，为临床医生和患者提供新的治疗策略。
INPLASY 注册号：INPLASY2021110015。
